Thank you @iwCLL2025 for the opportunity to present in Poland @wanglabcityofhope.bsky.social @ericalytical.bsky.social
September 14, 2025 at 2:04 PM
Thank you @iwCLL2025 for the opportunity to present in Poland @wanglabcityofhope.bsky.social @ericalytical.bsky.social
🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
October 16, 2025 at 8:29 AM
🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 18, 2025 at 3:02 PM
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
September 22, 2025 at 4:42 PM
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 11, 2025 at 6:03 PM
In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England.
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Watch here:
👉 buff.ly/FZdouqO 👈
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Missed out on #iwCLL2025?🩸
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
September 26, 2025 at 3:04 PM
Missed out on #iwCLL2025?🩸
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
September 30, 2025 at 5:04 PM
Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
November 4, 2025 at 9:29 AM
🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY:
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
👉 buff.ly/paPH5vx 👈
#CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky
It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
September 24, 2025 at 3:03 PM
It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
November 8, 2025 at 2:01 PM
🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies:
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
👉 buff.ly/BKMPQGT 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
November 5, 2025 at 1:19 PM
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
November 1, 2025 at 2:01 PM
It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings.
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
Watch the interview here:
🎥 buff.ly/sZGLLe2
#CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
October 28, 2025 at 4:48 PM
How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
Jacob Soumerai discussed this in a recent interview:
🎥 buff.ly/6qCplqB
#CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky
🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
October 24, 2025 at 1:04 PM
🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL:
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
👉 buff.ly/BiuqDZd 👈
#CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
October 13, 2025 at 8:29 AM
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
October 10, 2025 at 5:03 PM
We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
September 27, 2025 at 1:02 PM
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
September 20, 2025 at 2:01 PM
At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
We had a fantastic time at #iwCLL2025 last week!🇵🇱
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
September 19, 2025 at 3:05 PM
We had a fantastic time at #iwCLL2025 last week!🇵🇱
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
It's our first day onsite at #iwCLL2025 and we can't wait for two jam-packed days of expert interviews about all things CLL!🩸
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
September 13, 2025 at 8:29 AM
Jose Luis, Daniela and Víctor presenting HEMMOL results at #iwCLL2025
September 15, 2025 at 7:42 AM
Jose Luis, Daniela and Víctor presenting HEMMOL results at #iwCLL2025
Víctor Arenas’ communication to #iwCLL2025
September 12, 2025 at 1:29 PM
Víctor Arenas’ communication to #iwCLL2025
Daniela Vallejo’s communication to #iwCLL2025
September 12, 2025 at 1:27 PM
Daniela Vallejo’s communication to #iwCLL2025
Jose Luis Castaño contribution to #iwCLL2025
September 12, 2025 at 1:23 PM
Jose Luis Castaño contribution to #iwCLL2025